Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minetti, C.
Right arrow Articles by Bonilla, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minetti, C.
Right arrow Articles by Bonilla, E.
NEUROLOGY 1992;42:1751
© 1992 American Academy of Neurology

Immunologic study of vinculin in Duchenne muscular dystrophy

Carlo Minetti, MD, Kurenai Tanji, MD and Eduardo Bonilla, MD

Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, NY (Drs. Minetti, Tanji, and Bonilla)
Department of Pediatrics, Istituto G. Gaslini, Geneva, Italy (Dr. Minetti).

Using immunologic techniques, we studied vinculin, a cytoskeletal protein associated with the membrane-skeleton of the muscle fiber. We examined muscle biopsies from five patients with Duchenne muscular dystrophy (DMD), two with Becker's muscular dystrophy (BMD), three normal human muscle samples, and four biopsies from disease control patients. All DMD patients showed patchy and low-intensity immunostain at the sarcolemma of most fibers and, by immunoblot analysis, the content of vinculin was 42 to 61% of control values. There was no significant vinculin deficiency in samples from patients with BMD and other disease controls. The data suggest that vinculin content is reduced only in muscle where dystrophin is absent or sparse.

Supported by Center Grant NS 11766 from the National Institute for Neurological Diseases and Stroke, by a grant from the Muscular Dystrophy Association (E.B.), and by a grant from the Italian Muscular Dystrophy Telethon, project 32 (CM.).

Address correspondence and reprint requests to Dr. Eduardo Bonilla, Room 5-431, College of Physicians and Surgeons, New York, NY 10032.

Received November 7, 1991. Accepted for publication in final form February 13, 1992.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
B. D. Johnson, T. Scheuer, and W. A. Catterall
Convergent regulation of skeletal muscle Ca2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase
PNAS, March 15, 2005; 102(11): 4191 - 4196.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
I. N. Rybakova, J. R. Patel, and J. M. Ervasti
The Dystrophin Complex Forms a Mechanically Strong Link between the Sarcolemma and Costameric Actin
J. Cell Biol., September 4, 2000; 150(5): 1209 - 1214.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. Law, D. Allen, and J. Tidball
Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis
J. Cell Sci., January 6, 1994; 107(6): 1477 - 1483.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. P. Hoffman and J. Wang
Duchenne-Becker Muscular Dystrophy and the Nondystrophic Myotonias: Paradigms for Loss of Function and Change of Function of Gene Products
Arch Neurol, November 1, 1993; 50(11): 1227 - 1237.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by AAN Enterprises, Inc.